Enhanced Luminescent Detection of Circulating Tumor Cells by a 3D Printed Immunomagnetic Concentrator

Park, Chanyong; Abafogi, Abdurhaman Teyib; Ponnuvelu, Dinesh Veeran; Song, Ilchan; Ko, Kisung; Park, Sungsu

doi:10.3390/bios11080278

Cited by 13 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 3D‐printed immunomagnetic concentrator (3DPIC) was reported by Park and colleagues (Figure 2d) [ 35 ] for the luminescent detection of CTCs. This platform improves upon the CellSearch and MagSweeper methods in terms of required sample volume, needing only 1 mL of blood, demonstrating a relatively high flow rate of 5 mL min −1 , with a processing time of 30 min.…”

Section: Micro and Nano Biosensors For Liquid Biopsymentioning

confidence: 99%

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Clack

Soda

Kasetsirikul

et al. 2023

Small

View full text Add to dashboard Cite

from circulating biomarkers (CBs). CBs may be found in several minimally invasive bodily fluids including (but not limited to) blood, saliva, urine, pleural effusions, stool, and cerebrospinal fluid. CBs may include circulating tumor cells (CTCs), circulating tumor RNA/DNA (ctRNA/ctDNA), microRNAs (miRNAs), long non-coding RNAs (lncRNAs), proteins, exosomes, autoantibodies, all of which, are known for their diagnostic and prognostic potential. [1] Currently, clinicians and centralized hospitals practice tissue biopsy for diagnosis and characterization of the heterogeneity of the solid tumor which is crucial for personalized medicine. [1a] Despite the many decades of clinical practice, tissue-based biopsies are subject to sampling bias, suffer from the issue of low repeatability, and cause immense pain in patients as the process is invasive. One of the major concerns of biopsies, often ignored, is the entrance of tumor cells into the systemic circulation during the tissue-sampling process, leading to tumor metastasis. [2] To overcome these issues, the detection of CBs through liquid biopsy has shown promise as a potential replacement due to the rapid and semi or non-invasive sampling process and the repeated analysis of samples during therapeutic interventions aid in decision-making about a particular patient's progress.Due to the advancement of highly specific sequencing and gene amplification technologies, liquid biopsies can access more relevant cancer biomarkers, providing a much-needed alternative to tissue-based biopsy. [1b] These recent advances have led to the development of many miniaturized/ portable platforms. The clinical potential of these micro and nano devices is rapidly growing, but they face many challenges before transitioning to point-of-care (POC) platforms that are sensitive, rapid, and accurate, as discussed herein.Previously, our group [3] provided a critical review of circulating tumor DNA (ctDNA) and liquid biopsy opportunities, challenges, and recent advances in detection technologies. The review examines the potential of ctDNA as a marker in liquid biopsy, as well as the detection methods, challenges, and considerations. We further [1b] provided a comprehensive review of advanced liquid biopsy technologies for CBs detection. Others Liquid biopsy for the analysis of circulating cancer biomarkers (CBs) is a major advancement toward the early detection of cancer. In comparison to tissue biopsy techniques, liquid biopsy is relatively painless, offering multiple sampling opportunities across easily accessible bodily fluids such as blood, urine, and saliva. Liquid biopsy is also relatively inexpensive and simple, avoiding the requirement for specialized laboratory equipment or trained medical staff. Major advances in the field of liquid biopsy are attributed largely to developments in nanotechnology and microfabrication that enables the creation of highly precise chip-based platforms. These devices can overcome detection limitations of an individual biomarker by detecting multiple markers ...

show abstract

Section: Micro and Nano Biosensors For Liquid Biopsymentioning

confidence: 99%

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Clack

Soda

Kasetsirikul

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…Park et al [46] employed a digital light processing (DLP) 3D printer for the manufacture of a 3D-printed immunomagnetic concentrator (3DPIC) for ATP bioluminescence assay. This techniques correlates the intracellular ATP concentration of cells with their viability, exploiting the emitted light generated from the ATP-dependent oxidation of luciferin catalyzed by luciferase.…”

Section: Vat Photopolymerization and Biosensorsmentioning

confidence: 99%

3D Printing Technologies in Biosensors Production: Recent Developments

2022

View full text Add to dashboard Cite

Recent advances in 3D printing technologies and materials have enabled rapid development of innovative sensors for applications in different aspects of human life. Various 3D printing technologies have been adopted to fabricate biosensors or some of their components thanks to the advantages of these methodologies over the traditional ones, such as end-user customization and rapid prototyping. In this review, the works published in the last two years on 3D-printed biosensors are considered and grouped on the basis of the 3D printing technologies applied in different fields of application, highlighting the main analytical parameters. In the first part, 3D methods are discussed, after which the principal achievements and promising aspects obtained with the 3D-printed sensors are reported. An overview of the recent developments on this current topic is provided, as established by the considered works in this multidisciplinary field. Finally, future challenges on the improvement and innovation of the 3D printing technologies utilized for biosensors production are discussed.

show abstract

“…This 3D printed concentrator allows the cancer cells to get concentrated up to 100 times, thereby allowing the ATP luminescence assay to detect ten cells in the blood, which is ten times more sensitive than existing marketable kits. Thus, the 3D printed concentrator helps in enhancing the detection limit of the ATP luminescence assay for detecting circulating tumor cells [183]. Similarly, a 3D-printed microfluidic array was developed to detect multiple proteins with a very low detection limit.…”

Section: Cancer Diagnosis and 3d Printingmentioning

confidence: 99%

Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives

Safhi

2022

Pharmaceuticals

View full text Add to dashboard Cite

Three-dimensional (3D) printing is a technique where the products are printed layer-by-layer via a series of cross-sectional slices with the exact deposition of different cell types and biomaterials based on computer-aided design software. Three-dimensional printing can be divided into several approaches, such as extrusion-based printing, laser-induced forward transfer-based printing systems, and so on. Bio-ink is a crucial tool necessary for the fabrication of the 3D construct of living tissue in order to mimic the native tissue/cells using 3D printing technology. The formation of 3D software helps in the development of novel drug delivery systems with drug screening potential, as well as 3D constructs of tumor models. Additionally, several complex structures of inner tissues like stroma and channels of different sizes are printed through 3D printing techniques. Three-dimensional printing technology could also be used to develop therapy training simulators for educational purposes so that learners can practice complex surgical procedures. The fabrication of implantable medical devices using 3D printing technology with less risk of infections is receiving increased attention recently. A Cancer-on-a-chip is a microfluidic device that recreates tumor physiology and allows for a continuous supply of nutrients or therapeutic compounds. In this review, based on the recent literature, we have discussed various printing methods for 3D printing and types of bio-inks, and provided information on how 3D printing plays a crucial role in cancer management.

show abstract

Enhanced Luminescent Detection of Circulating Tumor Cells by a 3D Printed Immunomagnetic Concentrator

Cited by 13 publications

References 30 publications

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

Toward Personalized Nanomedicine: The Critical Evaluation of Micro and Nanodevices for Cancer Biomarker Analysis in Liquid Biopsy

3D Printing Technologies in Biosensors Production: Recent Developments

Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives

Contact Info

Product

Resources

About